secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001641172-25-009849
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients
--------------------------------------------------------------------------------

- Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.
- Study plans up to 30 participants; initial 1-year evaluation, possible extension to 3 years.
- First patient implants expected by July 2025; Principal Investigators Prof. David O'Neal and Assoc. Prof. Neale Cohen.
- CBGM is implantable, measures blood glucose directly (vs interstitial fluid), no wearable component.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225009849/0001641172-25-009849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225009849/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer